Herbalzym

An Exciting Natural Treatment for Brain Cancer

March 25, 2010, Featured in Cancer and Natural Medicines, 0 Comments

The brain and spinal column make up the central nervous system (CNS), where all vital functions of the body are controlled. When tumors arise in the central nervous system, they are especially problematic because a person’s thought processes and movements can be affected. These tumors can also be difficult to treat because the tissues surrounding a tumor that may be affected by surgery or radiation may play a vital role in functioning.

There are two broad types of cancers occurring within this system. Primary tumors originate in the central nervous system, whereas secondary tumors migrate from cancers located elsewhere in the body, such as breast cancers. Secondary, or metastatic, brain tumors, are more common than primary brain cancers. This section focuses on primary brain cancers. The brain is a soft, spongy mass of nerve cells and supportive tissue. It has three major parts: the cerebrum, the cerebellum, and the brain stem. The parts work together, but each has special functions.

The brain is composed of:

  •  The cerebrum, which is divided into two cerebral hemispheres. The cerebrum is the largest part of the brain and is divided into lobes where discrete functions occur. Higher reasoning takes place in the cerebrum.
  •  The cerebellum, or little brain, located beneath the cerebrum. The cerebellum controls coordination and balance.
  • The brain stem, which is the lowest portion of the brain and connects to the spinal cord, controls involuntary functions essential for life, such as the beating of the heart and breathing.
  • The meninges, membranes that surround and protect the brain and spinal cord. There are three meninges.

The types of primary brain cancers are classified according to the type of cells from which they originate. Oncologists describe the tumor based on its characteristics. For example, a noninfiltrating tumor can be expected to grow slowly and not invade surrounding structures. A well-differentiated tumor is also slow growing, but has the potential to be invasive. Anaplastic tumors are generally more aggressive.

Gliomas - Most brain tumors are gliomas, which originate in the glial cells (the supportive cells of the nervous system). Gliomas can be described as low-grade (slow-growing); intermediate-grade (more aggressive); or high-grade (very aggressive).

There are many different types of gliomas:

  1. Astrocytoma, the most common type of glioma, which usually begin in cells called astrocytes within the cerebrum, or the cerebellum. Glioblastoma multiforme is a form of very aggressive astrocytoma.
  2. Oligodendroglioma, a tumor that develops from oligodendrocytes. These cells are responsible for producing the myelin that surrounds nerves.
  3. Brain stem glioma, which begins in the glial cells in the brain stem.
  4. Ependymoma, which begins in the ependyma, the cells that line the passageways in the brain where cerebrospinal fluid is made and stored.
  5. Mixed tumors, which are composed of more than one of the glial cell types.

Nonglial tumors include:

  1. Acoustic schwannoma, which occurs in the vestibular nerve.
  2. Craniopharyngioma, which begins near the pituitary gland.
  3. Meningiomas, which originate in the meninges surrounding the brain and spinal column. Even though these tumors are generally benign, they may cause significant symptoms as they grow and press on the brain or spinal cord.
  4. Medulloblastoma, which arises from granular cells in the cerebellum.
  5. Primary CNS lymphoma
  6. The pineal and pituitary glands, located near the base of the brain, can also be the source of tumors.

Since brain and spinal cord tumors behave somewhat differently than tumors arising in other parts of the body, they are often referred to as low and high grade, rather than benign and malignant. Oncologists assign the terms low, intermediate, or high grade to a patient’s tumor based on parameters that predict how quickly the tumor can grow and its potential to spread to other parts of the brain.

Treating brain and spinal cord tumors can be difficult. The blood-brain barrier (BBB), which normally serves to protect the brain and spinal cord from damaging chemicals getting into those structures, also keeps out many types of potentially beneficial chemotherapy drugs. Surgery can be difficult if the tumor is near a delicate portion of the brain or spinal cord and radiation therapy can damage healthy tissue. However, research in the past two decades has improved the survival rates of patients with brain tumors. More refined surgeries, a better understanding of what types of tumors respond to chemotherapy, and precise delivery of radiation have resulted in longer life span and better quality of life for people with brain cancers. As we well know, there are many kinds of cancer; unfortunately they all come about because of the out-of-control growth of abnormal cells.

The causes of brain tumors are not known. By studying large numbers of patients, researchers have found certain risk factors that increase a person’s chance of developing a brain tumor. People with these risk factors have a higher-than-average risk of getting a brain tumor. For example, studies show that some types of brain tumors are more frequent among workers in certain industries, such as oil refining, rubber manufacturing, and drug manufacturing. Other studies have shown that chemists and embalmers have a higher incidence of brain tumors. Researchers also are looking at exposure to viruses as a possible cause. Because brain tumors sometimes occur in several members of the same family, researchers are studying families with a history of brain tumors to see whether heredity is a cause. At this time, scientists do not believe that head injuries cause brain tumors to develop. Recently, the alarm has been raised by some who fear that damage might be done to our brains from being exposed to Wi-Fi. The effect mobile phone radiation has on human health is the subject of recent interest and study, as a result of the enormous increase in cell phone usage throughout the world. Cell phones use electromagnetic radiation in the microwave range, and researchers believe this may be harmful to human health.

Treatment for a brain cancer depends on a number of factors. Among these are the type, location, and size of the tumor, as well as the patient’s age and general health. Treatment methods and schedules often vary for children and adults. Temodal (Temozolomide), an oral alkylating agent, is a standardized chemotherapy drug that is most commonly used to treat a type of brain cancer. However, current treatment for brain cancer works for a while and then usually fails. Clinically, what we see with patients with glioblastoma is that after surgery, radiation and chemotherapy with Temodal (Temozolomide), they live longer and a subset of them will actually live a year, two years or even longer. And then pretty much 100 percent of the patients relapse and no one knows why. When treated with Temodal (Temozolomide), they develop recurrent diseases even quicker, so Temodal (Temozolomide) make the cells that survive act in a more aggressive manner.

Protein ABCG2 is associated with resistance to drugs in brain cancer cells. This protein transports drugs across the cell’s membrane, which would otherwise shield the tumor cell from chemotherapy drugs. The researchers isolated cells from mice and human brain cancer tumors (glioblastomas). Some of these cells appeared to have the ability to renew themselves and resist chemotherapy, the team found, and ABCG2 appears to be a marker for these resistant cells. Temodal (Temozolomide) actually increased the number of drug-resistant cells. Because Temodal (Temozolomide) doesn’t target ABCG2, it may render surviving cells more resistant to treatments that do target the ABCG2 protein, and may boost the aggressiveness of surviving cancer cells, making tumor recurrence more likely. Life is complicated; brain tumors are complicated too.

The Scientifically Formulated HerbalZym Therapy 

The HerbalZym protocol that we are about to propose is simple to implement. 

Over the past 10 years, clinical experimentation has proven that Herbalzym formulas have remarkable therapeutic effect in patients with brain cancer including glioblastoma, and have been used with much success to treat brain cancer. This has now been proven over and over again. Oral treatments for brain cancer are difficult to develop because of the blood brain barrier (BBB). Fortunately, we do have some new options.

ABCG2, or breast cancer resistance protein (BCRP), is an ABC transporter that has been the subject of intense study since its discovery a decade ago. With high normal tissue expression in the brain endothelium, gastrointestinal tract, and placenta, ABCG2 is believed to be important in the protection from xenobiotics, regulating oral bioavailability, forming part of the blood-brain barrier (BBB), the blood-testis barrier, and the maternal-fetal barrier. Notably, ABCG2 is often expressed in stem cell populations, where it likely plays a role in xenobiotic protection. If you can inhibit ABCG2 protein, relapse after treatment with temozolomide could be prevented. This could open doors to treatment. This is exciting stuff.  ABCG2 can be inhibited by ChemoZym

The over expression of Cox-2 is a bad prognostic sign in brain cancer. This is especially true in childhood brain cancer. The AKT master enzyme in cancer growth and development is over activated in brain cancers. AKT, via its activation of Hypoxia-inducible factor-1(HIF-1), promotes the synthesis of VEGF, a critical blood vessel growth factor necessary for the proliferation and survival of brain cancer cells. AKT is the master biochemical enzyme for the growth and survival of cancer cells, including gliomas.

HIF-1 is the major hypoxia-regulated transcription factor that regulates cellular responses to low oxygen environments. HIF-1 is composed of two subunits: hypoxia-inducible HIF-1alpha and constitutively-expressed HIF-1beta. During hypoxic conditions, HIF-1alpha heterodimerizes with HIF-1beta and translocates to the nucleus where the HIF-1 complex binds to the hypoxia-response element (HRE) and activates expression of target genes implicated in cell growth and survival. HIF-1alpha protein expression is elevated in many solid tumors, including those of the cervix and brain, where cells that are the greatest distance from blood vessels, and therefore the most hypoxic, express the highest levels of HIF-1alpha. Therapeutic blockade of the HIF-1 signaling pathway in cancer cells therefore provides an attractive strategy for development of anticancer drugs. Cox-2, AKT and HIF-1 can be inhibited by HerbalZym protocol.

If you can eliminate the factors that suppress immune responsiveness, the innate and adaptive immune systems will clear the cancer cells from the body. They do it every day of your life unless something goes wrong. In the HerbalZym protocol, we are attempting to kill brain cancer cells via oxidative stress mediated by autophagy, apoptosis and necrosis. Clearly, HerbalZym protocol knocks down the bulk of the tumor mass, and should be able to clean up the residual cancer cells.

CurcuZym Take 20 ml (5 ml 4 times) daily

ChemoZym Take 6 tablets (2 tablets 3 times) daily

GenisZym Take 20 ml (5 ml 4 times) daily

GlugerZym Take 20 ml (5 ml 4 times) daily

SinnolZym Take 20 ml (5 ml 4 times) daily

TeanZym Take 20 ml (5 ml 4 times) daily

 Anacin Take 6 tablets (2 tablets, 3 times) daily

 Sodium Selenite (Selenium) Take 6 drops (3 drops twice) daily

Sodium selenite is a salt, a colourless solid, and the most common water-soluble selenium compound. Selenium is a trace element with both indirect enzymatic anti-oxidant, and direct oxidant properties. Selenium is necessary for the functioning of many enzymes. In high concentrations, it depletes glutathione thereby inducing autophagy and apoptosis. Liquid sodium selenite could be introduced into the nose to treat brain cancer. Sodium selenite does not harm normal neurons, but it does promote the death of gliomas by the depletion of glutathione.

References

1. Hypoxia inducible factors in cancer stem cells.

2. Identification of small molecule compounds that inhibit the HIF-1 signaling pathway.

3. The expression and significance of HIF-1alpha and GLUT-3 in glioma.

4. ABCG2: the key to chemoresistance in cancer stem cells?

5. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.

6. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

7. ABCG2: a perspective.

8. ABCG2: structure, function and role in drug response.

9. Angiogenesis in brain tumours.

10. Paracetamol (acetaminophen) penetrates readily into the cerebrospinal fluid of children after intravenous administration.

11. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.

12. Expression of VEGFR3 in glioma endothelium correlates with tumor grade.

13. Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.

14. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas.

15. Angiogenesis in gliomas: biology and molecular pathophysiology.

16. Cyclooxygenase-2 inhibition to treat radiation-induced brain necrosis and edema.

17. Interaction of glutathione and sodium selenite in vitro investigated by electrospray ionization tandem mass spectrometry.

18. Decreased glutathione levels potentiate the apoptotic efficacy of selenium: possible involvement of p38 and JNK MAPKs–in vitro studies.

19. Sodium selenite induces superoxide-mediated mitochondrial damage and subsequent autophagic cell death in malignant glioma cells.

20. Methylprednisolone and indomethacin inhibit oxidative stress mediated apoptosis in rat C6 glioblastoma cells.

21. Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro.

22. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.

23. Evaluating selenium poisoning.

24. Accidental death from acute selenium poisoning.

25. Cyclooxygenase-2 (COX-2) overexpression in childhood brain tumors.

26. Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-XL.

27. Autophagic programmed cell death by selective catalase degradation.

28. Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme.

29. Differential cyclooxygenase-2 enzyme expression in radiosensitive versus radioresistant glioblastoma multiforme cell lines.

30. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.

31. Overexpression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in vitro.

32. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance.

33. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line.

34. Selenium causes growth inhibition and apoptosis in human brain tumor cell lines.

35. Dexamethasone pre-treatment interferes with apoptotic death in glioma cells.

36. Symptomatic treatment of brain tumor patients with sodium selenite, oxygen, and other supportive measures.

37. Apoptosis induced by selenium in human glioma cell lines.

38. Effect of selenium on malignant tumor cells of brain.

39. Uptake and distribution of sodium selenite in rat brain tumor.

Leave a Reply